Polyphenol Application in Kidney Disease Patients
We are honored to welcome Professor Andrzej Jaroszyński from Jan Kochanowski University in Poland at our 18th World Congress on Polyphenols Applications 2025 wich will be held in Malta on 2-3 October.
Summary
Chronic kidney disease (CKD) is a global concern whose importance cannot be overestimated. CKD affects >10% of the general population worldwide, amounting to > 800 million individuals. CKD is associated with increased risk of death mainly due to the development of cardiovascular disease, infections, and cancer.
Xantohumol (XN) is a prenylated flavonoid with anti-inflammatory, anti–oxidant, anti–fibrotic, anti–proliferative, anti-microbial, anti-viral, and immunomodulatory properties. Immunological abnormalities, inflammation, oxidative stress and fibrosis are processes that take part in the etiopathogenesis of most renal diseases, including glomerulonephritis and CKD. Growing evidence exists that XN acts on numerous cellular and biochemical pathways that take part in the pathogenesis of kidney diseases. We would like to present both the theoretical basis for the use of XN in the supportive therapy of kidney diseases and our preliminary clinical experience in this field.
Prof. Jaroszyński's current research investigates Xanthohumol (Xn), a natural compound from hops with promising anti-inflammatory, antioxidative, and mild anti-coagulation properties. Prof. Jaroszyński's work highlights how Xn inhibits inflammatory pathways, reduces cytokine production, and enhances antioxidative enzyme activity—potentially offering a valuable adjuvant therapy for various critical illnesses.
With extensive clinical experience and a commitment to finding multidisciplinary solutions for critically ill patients, Prof. Jaroszyński's presentation will provide valuable insights into the future of critical care medicine and innovative approaches to managing inflammatory responses.
